MedTrace Logo

Effect of In-Place Slow Jogging on Metabolic Dysfunction-Associated Steatotic Liver Disease

NCT06994234 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2025-05-29

No results posted yet for this study

Summary

Evaluating the Effectiveness, Safety, and Feasibility of Stationary Ultra-Slow Running in Treating MASLD Patients.

Conditions

  • Metabolic Dysfunction-Associated Steatotic Liver Disease

Interventions

BEHAVIORAL

In-Place Slow Jogging

ultra-jogging training was carried out 5 times a week, and each training session lasted for 30 minutes.

Sponsors & Collaborators

  • Shanghai East Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2027-06-20
Completion
2028-06-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06994234 on ClinicalTrials.gov